Posted On: 09/27/2016 9:02:51 PM
Post# of 273318
Madrigal Pharmaceuticals Inc (MDGL) 11.72 $MDGL
Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform
GlobeNewswire - Mon Sep 19, 6:30AM CDT
- PEN-866 positioned to begin clinical trials in 2017 -
MDGL: 11.72 (-0.08)
Richard S. Levy, M. D., Appointed to Madrigal Board of Directors
GlobeNewswire - Thu Aug 11, 6:30AM CDT
MADRIGAL PHARMACEUTICALS, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for cardiovascular, metabolic and liver diseases, today announced the appointment of Richard S. Levy, M. D., to its board of directors, effective immediately.
MDGL: 11.72 (-0.08)
Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform
GlobeNewswire - Mon Sep 19, 6:30AM CDT
- PEN-866 positioned to begin clinical trials in 2017 -
MDGL: 11.72 (-0.08)
Richard S. Levy, M. D., Appointed to Madrigal Board of Directors
GlobeNewswire - Thu Aug 11, 6:30AM CDT
MADRIGAL PHARMACEUTICALS, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for cardiovascular, metabolic and liver diseases, today announced the appointment of Richard S. Levy, M. D., to its board of directors, effective immediately.
MDGL: 11.72 (-0.08)
(0)
(0)
